Infinimmune, a biotechnology company pioneering new methods for antibody drug discovery and development, announced today the appointment of Tim Sullivan, Ph.D., as Chief Business Officer. In this newly created role, Dr. Sullivan, who has decades of experience as a senior executive in the biotechnology and pharmaceutical industry, will be responsible for corporate and business development initiatives, as well as corporate and product strategic planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903196986/en/

Dr. Tim Sullivan, Chief Business Officer, Infinimmune (Photo Credit: Infinimmune)

“We’re thrilled to have Tim lead Infinimmune’s business development efforts, driving strategic growth initiatives and fostering key partnerships to advance our mission of developing fully human antibody therapies,” said Wyatt McDonnell, CEO & Co-Founder, Infinimmune. “His deep industry knowledge and proven track record in business development and strategy will be invaluable as we continue to expand our capabilities and deliver innovative antibody therapies to patients.”

“I am excited to join Infinimmune at such a dynamic time. The company’s commitment to pioneering advances in antibody development is truly inspiring, and I look forward to contributing to its continued success by leading our business development initiatives,��� said Sullivan.

Prior to joining Infinimmune, Dr. Sullivan served as Chief Business Officer at Spring Discovery, a biotech company, where he executed partnerships with multiple groups, including Gilead and the Gates Foundation, and built an efficient engine for identifying new partnership opportunities. He was also Vice President of Business Development at Arcus Biosciences, where he played a pivotal role in expanding the company’s strategic partnerships and pipeline. Prior to Arcus, he was the Senior Director of External R&D Innovation at Pfizer, where he was instrumental in identifying and securing external collaborations that fueled the company’s innovation pipeline.

He also held the position of Director at Takeda, where he was responsible for sourcing and integrating cutting-edge technologies and therapeutic assets. Additionally, he served as Research Director at ChemoCentryx, contributing to the advancement of novel immunology-based therapies.

Dr. Sullivan received his Ph.D. in Molecular and Cell Biology at the University of California, Berkeley, where he trained under Jim Allison. He also received a B.A in Psychology and Biology from the University of Notre Dame.

About Infinimmune

Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903196986/en/